Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent sign...
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo®(nivolumab) in combination with cisplatin and gemcitabine ...
TROPION-Lung01 Phase III trial had a local progressive or metastatic non-small cell lung cancer with at least one treatment history in the past ( Datopot...
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with E...
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...
Eisai Co., Ltd. (CEO: Haruo Naito) and Biogen Inc. (CEO: Christopher A. Viehbacher) announced that the Ministry of Food and Drug Safety (MFDS) in South K...
The ALIGN study, focusing on atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, revealed a remarkable 36.1% redu...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments wi...
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with pa...
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC por...
May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations. Hepatitis is an inf...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
InnoCare Pharma, a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...
© 2025 Biopharma Boardroom. All Rights Reserved.
